RedHill Biopharma Announces Approval of Compassionate Use of Opaganib for COVID-19 in Italy
by Press Release from Outbreak News Today on (#51T2C)
RedHill Biopharma Ltd., a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that it has received authorization from the Italian National Institute for Infectious Diseases and Central Italian Ethics Committee (EC) for an expanded access program (EAP) allowing immediate compassionate use of its investigational drug, opaganib (Yeliva(R), ABC294640), in Italy for patients with confirmed ["]
The post RedHill Biopharma Announces Approval of Compassionate Use of Opaganib for COVID-19 in Italy appeared first on Outbreak News Today.